Literature DB >> 15155382

Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans.

Francesco Cipollone1, Maria Fazia, Annalisa Iezzi, Giovanni Ciabattoni, Barbara Pini, Chiara Cuccurullo, Sante Ucchino, Francesco Spigonardo, Mariella De Luca, Cesaria Prontera, Francesco Chiarelli, Franco Cuccurullo, Andrea Mezzetti.   

Abstract

OBJECTIVE: Inducible cyclooxygenase (COX-2) catalyzes the first step in prostanoid biosynthesis and is considered a proinflammatory enzyme. COX-2 and type 1 inducible PGE synthase (mPGES-1) have a role in metalloproteinase (MMP) release leading to plaque rupture. In contrast, lipocalin-type PGD synthase (L-PGDS) has been shown to exert antiinflammatory actions. Thus, in this study we investigated whether a shift from a PGDS-oriented to a PGES-oriented profile in arachidonate metabolism leads to inflammatory activation in rupture-prone plaque macrophages. METHODS AND
RESULTS: Atherosclerotic plaques were obtained from 60 patients who underwent carotid endarterectomy, symptomatic (n=30) and asymptomatic (n=30) according to evidence of recent transient ischemic attack or stroke. Plaques were analyzed for COX-2, mPGES-1, L-PGDS, PPARgamma, IkappaBalpha, NF-kappaB, and MMP-9 by immunocytochemistry, Western blot, reverse-transcriptase polymerase chain reaction, enzyme immunoassay, and zymography. Prostaglandin E2 (PGE2) pathway was significantly prevalent in symptomatic plaques, whereas PGD2 pathway was overexpressed in asymptomatic ones, associated with NF-kappaB inactivation and MMP-9 suppression. In vitro COX-2 inhibition in monocytes was associated with reduced MMP-9 release only when PGD2 pathway overcame PGE2 pathway.
CONCLUSIONS: These results suggest that COX-2 may have proinflammatory and antiinflammatory properties as a function of expression of downstream PGH2 isomerases, and that the switch from L-PGDS to mPGES-1 in plaque macrophages is associated with cerebral ischemic syndromes, possibly through MMP-induced plaque rupture.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155382     DOI: 10.1161/01.ATV.0000133192.39901.be

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  33 in total

Review 1.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

2.  Nrf2 is essential for the expression of lipocalin-prostaglandin D synthase induced by prostaglandin D2.

Authors:  Kyun Ha Kim; Ruxana T Sadikot; Lei Xiao; John W Christman; Michael L Freeman; Jefferson Y Chan; Yu-Kyoung Oh; Timothy S Blackwell; Myungsoo Joo
Journal:  Free Radic Biol Med       Date:  2013-09-09       Impact factor: 7.376

3.  Immunomodulation strategies for preventing vascular disease of the brain and heart: workshop summary.

Authors:  John Hallenbeck; Gregory Del Zoppo; Tom Jacobs; Antoine Hakim; Stephen Goldman; Ursula Utz; Ahmed Hasan
Journal:  Stroke       Date:  2006-11-02       Impact factor: 7.914

4.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

5.  Targeted deletions of cyclooxygenase-2 and atherogenesis in mice.

Authors:  Yiqun Hui; Emanuela Ricciotti; Irene Crichton; Zhou Yu; Dairong Wang; Jane Stubbe; Miao Wang; Ellen Puré; Garret A FitzGerald
Journal:  Circulation       Date:  2010-06-07       Impact factor: 29.690

Review 6.  Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.

Authors:  Francesco Cipollone; Maria Luigia Fazia
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

7.  Inducible nitric oxide synthase gene deletion exaggerates MAPK-mediated cyclooxygenase-2 induction by inflammatory stimuli.

Authors:  Brian D Lamon; Rita K Upmacis; Ruba S Deeb; Hilal Koyuncu; David P Hajjar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-11       Impact factor: 4.733

Review 8.  Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia.

Authors:  Helen Vosper
Journal:  Br J Pharmacol       Date:  2009-07-20       Impact factor: 8.739

9.  Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study.

Authors:  Megan E Rudock; Yongmei Liu; Julie T Ziegler; Stewart G Allen; Allison B Lehtinen; Barry I Freedman; J Jeffrey Carr; Carl D Langefeld; Donald W Bowden
Journal:  Atherosclerosis       Date:  2008-07-26       Impact factor: 5.162

10.  Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis.

Authors:  Satori Tokudome; Motoaki Sano; Ken Shinmura; Tomohiro Matsuhashi; Shintaro Morizane; Hidenori Moriyama; Kayoko Tamaki; Kentaro Hayashida; Hiroki Nakanishi; Noritada Yoshikawa; Noriaki Shimizu; Jin Endo; Takaharu Katayama; Mitsushige Murata; Shinsuke Yuasa; Ruri Kaneda; Kengo Tomita; Naomi Eguchi; Yoshihiro Urade; Koichiro Asano; Yasunori Utsunomiya; Takeshi Suzuki; Ryo Taguchi; Hirotoshi Tanaka; Keiichi Fukuda
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.